CORE 2
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients with Severe Hypertriglyceridemia
- Stage
- klaar
- Medicine
- Olezarsen (ISIS 678354)
- Population
- ASCVD
- Phase
- III
- First Patient In
- 14 June 2023
- Last Patient In
- 10 June 2024
- Last Patient Last Visit
- 15 October 2025
National Lead
prof. dr. E.S.G. Stroes
Cardioloog
Study Director
drs. K.W. Wu
Cardioloog
Office Contact
